KIAWAH ISLAND, S.C. — Drug-eluting implants in various stages of study and approval may provide efficient, sustained drug delivery, overcoming barriers to penetration, according to a speaker at Kiawah Eye.
“Only 0.001% of a topical drug is thought to be accessing the retina, and 5% accesses the anterior segment. And then there are the other barriers to entry: patient confusion, poor compliance, challenges with instillation of drops, side effects yielding poor compliance and perhaps premature discontinuation of drops,” Neel R. Desai, MD, said.
One technology that is FDA